ResMed Inc. (NYSE:RMD) Shares Bought by WoodTrust Financial Corp

WoodTrust Financial Corp lifted its holdings in shares of ResMed Inc. (NYSE:RMD) by 1.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,620 shares of the medical equipment provider’s stock after buying an additional 100 shares during the period. WoodTrust Financial Corp’s holdings in ResMed were worth $1,743,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in RMD. True Wealth Design LLC raised its stake in ResMed by 2,200.0% during the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 110 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of ResMed during the third quarter valued at about $34,000. BankPlus Trust Department acquired a new stake in ResMed in the fourth quarter worth about $44,000. Rosenberg Matthew Hamilton bought a new position in ResMed in the 4th quarter valued at about $54,000. Finally, Capital Performance Advisors LLP acquired a new position in ResMed during the 3rd quarter valued at about $60,000. 54.98% of the stock is currently owned by institutional investors and hedge funds.

ResMed Price Performance

RMD stock opened at $231.31 on Wednesday. The firm has a 50-day moving average of $237.07 and a two-hundred day moving average of $240.02. The firm has a market capitalization of $33.97 billion, a PE ratio of 27.31, a P/E/G ratio of 1.53 and a beta of 0.70. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. ResMed Inc. has a one year low of $172.19 and a one year high of $263.05.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. On average, analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.92%. ResMed’s dividend payout ratio is 25.03%.

Insider Activity at ResMed

In other ResMed news, insider Kaushik Ghoshal sold 9,113 shares of ResMed stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $235.40, for a total transaction of $2,145,200.20. Following the transaction, the insider now owns 9,725 shares of the company’s stock, valued at $2,289,265. The trade was a 48.38 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the completion of the sale, the chief executive officer now directly owns 455,472 shares of the company’s stock, valued at $107,842,105.44. This trade represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 19,186 shares of company stock valued at $4,541,226. Company insiders own 0.71% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Piper Sandler upped their price target on shares of ResMed from $252.00 to $260.00 and gave the stock a “neutral” rating in a research note on Friday, January 31st. Stifel Nicolaus started coverage on ResMed in a research note on Friday, December 13th. They set a “hold” rating and a $250.00 price target for the company. JPMorgan Chase & Co. lifted their price target on ResMed from $270.00 to $286.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. The Goldman Sachs Group started coverage on ResMed in a report on Thursday, January 16th. They issued a “buy” rating for the company. Finally, UBS Group raised ResMed from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 31st. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, ResMed has a consensus rating of “Moderate Buy” and a consensus target price of $244.73.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.